

Financial Tear Sheet

Corporate Profile

Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. The Company's objective is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. The Company is currently advancing livoletide (<http://www.millendo.com/our-programs/livoletide.php>) for the treatment of Prader-Willi syndrome (<http://www.millendo.com/our-programs/disease-areas.php?pws>) and nevanimibe (<http://www.millendo.com/our-programs/nevanimibe.php>) for the treatment of classic congenital adrenal hyperplasia (<http://www.millendo.com/our-programs/disease-areas.php?cah>) and endogenous Cushing's syndrome (<http://www.millendo.com/our-programs/disease-areas.php?cs>). For more information, please visit www.millendo.com (<http://www.millendo.com/>).

Primary IR Contact

Stephanie Ascher
Phone: 212-362-1200
E-mail: stephanie@sternir.com
(<mailto:stephanie@sternir.com>)

Stock Performance

MLND (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$10.10
Change (%)	▼ 1.09 (9.74%)
Volume	20,668
52 Week High	\$17.40
52 Week Low	\$6.77
Market Cap	\$144,511,151
Rolling EPS	-12.29
PE Ratio	0
Shares Outstanding	12,914,312

Data as of 01/22/19 4:00 p.m. ET



Recent Headlines

01/17/19

Millendo Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

12/07/18

Millendo Therapeutics Announces Successful Merger Completion

11/14/18

Millendo Therapeutics Strengthens Executive Team with Key Appointments

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
01/17/19	4
01/17/19	4
01/17/19	4
01/17/19	4

Data provided by Nasdaq. Minimum 15 minutes delayed.